Medication info

Pernobon Injection 30 mg (Polynate Calcium)

Prescription medication
Ingredient · strength
Calcium Folinate›32mg / 1 ampoule
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow transparent injection solution in a brown ampoule
Packaging
2 mL - 50 ampoules per box
Approval status
Active

MFDS item code 199301651 · Notified 1993.07.29 · Insurance code 647802501

Summary

Main use
Combination therapy with 5-FU for advanced colorectal cancer; mitigation of toxicity from folate metabolism antagonists
Who uses it
Adults
Adult dosage
(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the conventional dose of methotrexate (a folate antagonist), administer 6-12mg per dose as folinate by intramuscular injection every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equivalent to the dose of methotrexate administered. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg per dose as folinate by intravenous injection every 3 hours for 9 doses, then by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions considered to be caused by methotrexate occur, increase the dose and extend the treatment period. 3. Concomitant use with 5-Fluorouracil (5-FU) in advanced colorectal cancer: Select one of the following two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablets) In the event of an overdose of a folate antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or lower. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If, after 24 hours, the serum creatinine concentration has increased by 50% compared with before methotrexate administration, or if the serum methotrexate concentration at 24 hours is 5X10-6M/L or higher, administer a high dose of calcium folinate. As oral administration of 25mg or more is not recommended, administer it parenterally. Provide fluids to maintain urine output of 1800-2000mL/㎡ per day, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate level is 5×10-8M/L(0.05μM/L).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Combination therapy with 5-FU for advanced colorectal cancer; mitigation of toxicity from folate metabolism antagonists

  • Toxicity of antifolate agents
View approved original text

This medication helps to reduce the side effects of antifolate drugs. It is also used in combination with 5-Fluorouracil (5-FU) to enhance treatment effects during advanced colon cancer therapy. Available in injectable and tablet forms, it can be administered according to the patient's condition. In summary, this drug is used to reduce the toxicity of antifolate agents and assist in the treatment of advanced colon cancer.

Dosage and Administration

Adult dosage

(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the conventional dose of methotrexate (a folate antagonist), administer 6-12mg per dose as folinate by intramuscular injection every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equivalent to the dose of methotrexate administered. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg per dose as folinate by intravenous injection every 3 hours for 9 doses, then by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions considered to be caused by methotrexate occur, increase the dose and extend the treatment period. 3. Concomitant use with 5-Fluorouracil (5-FU) in advanced colorectal cancer: Select one of the following two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablets) In the event of an overdose of a folate antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or lower. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If, after 24 hours, the serum creatinine concentration has increased by 50% compared with before methotrexate administration, or if the serum methotrexate concentration at 24 hours is 5X10-6M/L or higher, administer a high dose of calcium folinate. As oral administration of 25mg or more is not recommended, administer it parenterally. Provide fluids to maintain urine output of 1800-2000mL/㎡ per day, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate level is 5×10-8M/L(0.05μM/L).

Precautions

This medication is not suitable for treating pernicious anemia or megaloblastic anemia resulting from vitamin B12 deficiency. Caution is needed as hematological conditions may improve even if neurological symptoms continue. In the case of the injectable form, glass shards may mix in upon breaking the container, requiring extreme caution, especially when used in children or elderly patients. Pregnant or breastfeeding women should not use this medication in combination with 5-FU and should use it cautiously for toxicity reduction of antifolates. Allergic reactions such as rashes or anaphylaxis may occur, and any unusual symptoms should be reported to medical personnel immediately. There may be pain at the injection site, and rarely fever or central nervous system symptoms (paralysis, excitement, depression) may appear. When used with 5-FU, side effects such as diarrhea, dermatitis, mucositis, and leukopenia may occur, necessitating adjustment of the 5-FU dosage if symptoms are severe. This medication should be used under the guidance of a physician experienced in chemotherapy alongside methotrexate, and blood levels of methotrexate should be regularly monitored for treatment efficacy and side effect management. Patients with ascites or renal failure may have delayed drug elimination, possibly necessitating high-dose intravenous administration. As this drug shares a transporter with methotrexate, resistance to methotrexate may also imply resistance to this drug. If the patient has poor drug absorption or severe vomiting, non-oral administration is recommended, and higher doses should be administered intravenously. In particular, for patients with central nervous system tumors, repeated doses may result in drug accumulation and reduced anticancer efficacy, thus overdose should be avoided. This medication is not indicated for treatment of macrocytic anemia due to certain DNA synthesis inhibitors. It does not alleviate abnormal reactions such as nephrotoxicity caused by methotrexate and other hematologic toxicities. Due to its potential to enhance hepatic metabolism, it may lower blood concentrations of certain anticonvulsants, thus blood levels should be monitored and dosage adjustments may be necessary when given at high doses. Since it can increase the effects and side effects of 5-FU, caution is warranted when co-administering. Pregnant or breastfeeding patients should only use this drug when its benefits outweigh risks, as the impact on the fetus or newborn has not been fully elucidated. Store out of reach of children and do not transfer medications from their original containers to maintain quality and safety. When administered intravenously, care must be taken not to exceed a rate of 160 mg per minute due to calcium content, and intrathecal administration is prohibited.

Side effects

  • Anaphylactic reactions
  • urticaria
  • vascular pain
  • transient pain
  • fever
  • paresis
  • agitation
  • depression
  • diarrhea
  • skin reactions
Show 7 more
  • dry skin
  • stomatitis
  • conjunctivitis
  • mucositis
  • mild hematotoxicity
  • leukopenia
  • vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be light-sensitive and should be stored in a light-protective container. Also, avoid storing the medication in very hot or cold places; it is best stored safely at room temperature.

Appearance and packaging

Appearance

A colorless to pale yellow transparent injection solution in a brown ampoule

Package unit

2 mL - 50 ampoules per box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.